Metabolism - Clinical and Experimental
Volume 52, Issue 9 , Pages 1147-1152, September 2003

Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action☆

  • C.Hamish Courtney

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • David R McCance

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • A.Brew Atkinson

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • Jonathan Bassett

      Affiliations

    • Montalto Health Clinic, Balynahinch, Co. Down, United Kingdom
    • ,
  • Cieran N Ennis

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • Brian Sheridan

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • Patrick M Bell

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • Corresponding Author InformationAddress reprint requests to Patrick M. Bell, MD, East Wing Office, Royal Victoria Hospital, Belfast, UK BT12 6BA

Received 27 September 2002; accepted 22 April 2003.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported by a Royal Victoria Hospital Research Fellowship (to C.H.C.), Royal Victoria Hospital Metabolic Unit Research Fund, and Pfizer UK (to C.H.C. and P.M.B.).

PII: S0026-0495(03)00190-2

doi:10.1016/S0026-0495(03)00190-2

Metabolism - Clinical and Experimental
Volume 52, Issue 9 , Pages 1147-1152, September 2003

Article Tools

* Image Usage & Resolution